Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 3, 2008, Pages 349-354

  Saif, Muhammad Wasif ^a   Hashmi, Shahrukh ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRIFFIN HOSPITAL   (United States)

Author keywords

Colon cancer; Hyperexcitability syndrome; Myotonia; Oxaliplatin; Peripheral neuropathy; Sodium channels

Indexed keywords

ANTICONVULSIVE AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CITALOPRAM; DEXTROPROPOXYPHENE; DIPHENHYDRAMINE; GABAPENTIN; GEMCITABINE; GLIPIZIDE; GLUCONATE CALCIUM; LANSOPRAZOLE; LEVOTHYROXINE; LORAZEPAM; MAGNESIUM SULFATE; OXALIPLATIN; PREGABALIN;

ADULT; ARM BURNING SENSATION; ARM SHAKING; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; EYELID; EYELID MYOKEMIA; FEMALE; HAND GRIP; HAND MUSCLE; HAND SPASM; HAND TREMOR; HUMAN; HYPEREXCITABILITY SYNDROME; JOINT STIFFNESS; LEG SHAKING; MOTOR NERVE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MUSCLE INNERVATION; MUSCLE SPASM; MUSCLE TONE; MYOKYMIA; MYOTONIA; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; NEUROTOXICITY; ORAL PARESTHESIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARESTHESIA; PRIORITY JOURNAL; PTOSIS; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SLURRED SPEECH; TEETH CLATTERING; TIC; TREATMENT OUTCOME; VISUAL FIELD; VOICE CHANGE;

ADENOCARCINOMA; ADULT; ANTICONVULSANTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CALCIUM GLUCONATE; DEOXYCYTIDINE; DIPHENHYDRAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HISTAMINE H1 ANTAGONISTS; HUMANS; MAGNESIUM SULFATE; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PSYCHOMOTOR AGITATION;

EID: 37249020448     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0584-7     Document Type: Review

References (32)

1. Package insert. Eloxatin (oxaliplatin). Sanofi-Synthelabo, New York, July 2004
2. Bleiberg H, de Gramont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32-39
3. Becouarn Y, Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25:23-31
4. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
5. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(5 suppl 15):21-33
6. Leonard GD, Wright MA, Quinn MG, Harold N, Schuler B, Thomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):116
7. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387-392
8. Auger RG (1994) Diseases associated with excess motor unit activity. Muscle Nerve 17:1250-1263
9. Zielasek J, Martini R, Suter U et al (2000) Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 23:696-701
10. Reeback J, Benton S, Swash M et al (1979) Penicillamine-induced neuromyotonia. BMJ 1:1464-1465
11. Caldron PH, Wilbourn AJ (1988) Gold neurotoxicity and myokymia. J Rheumatol 15:528-529
12. Bostock H, Burke D, Hales JP (1994) Differences in behaviour of sensory and motor axons following release of ischaemia. Brain 117:225-234
13. Nagado T, Arimura K, Sonoda Y et al (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122:2057-2066
14. Maddison P, Newsom-Davis J, Mills KR (1999) Strength-duration properties of peripheral nerve in acquired neuromyotonia. Muscle Nerve 22:823-830
15. Hart IK, Waters C, Vincent A et al (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238-246
16. Vincent A (2000) Understanding neuromyotonia. Muscle Nerve 23:655-657
17. Hart IK (2000) Acquired neuromyotonia. A new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 319:209-216
18. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7):1767-1774
19. Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6(2):146-151
20. Mariani G, Garrone O, Granetto C et al (2000) Oxaliplatin-induced neuropathy: could gabapentin be the answer. Proc Am Soc Clin Oncol 19:609, (abstract 2397)
21. Fehrenbacher JC, Taylor CP, Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1-2):133-141
22. Frampton JE, Foster RH (2005) Pregabalin in the treatment of postherpetic neuralgia. Drugs 65(1):111-120
23. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of fble- and fixed-dose regimens. Pain 115(3):254-263
24. Wesche D, Bockbrader H (2005) A pharmacokinetic comparison of pregabalin and gabapentin. http://www.ampainsoc.org/abstract/2005/data/684/index.html. Accessed 22 June
25. Lahrmann H, Albrecht G, Drlicek M, Oberndorfer S, Urbanits S, Wanschitz J et al (2001) Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 24:834-838
26. Auger RG (1994) AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve 17:1250-1263
27. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ et al (1995) Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 38:714-722
28. Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Therap Clin Risk Manage 1(4):249-248
29. FDA approval letter of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy. Department of Health & Human Services. http://www.fda.gov/cder/foi/appletter/2004/21446ltr.pdf
30. Shneker B, McAuley JW (2005) Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39(12):2029-2037
31. Saif MW (2004) Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 4(4):576-582
32. CONCEPT Comparison of oxaliplatin vs. conventional methods with calcium/magnesium in first-line metastatic colorectal cancer. http://www.clinicaltrials.gov/ct/show/NCT00129870. Accessed 11 Aug 2007